A systematic review of ongoing clinical trials in optic pathway gliomas

Abstract

Introduction Optic pathway gliomas (OPGs), also known as Visual Pathway Gliomas, are insidious, debilitating tumours. They are most commonly WHO grade 1 pilocytic astrocytomas and frequently occur in patients with neurofibromatosis type 1. The location of OPGs within the optic pathway typically precludes complete resection or optimal radiation dosing, hence outcomes remain poor compared to many other low-grade gliomas. The aim of this systematic review was to formulate a comprehensive list of all current ongoing clinical trials that are specifically looking at clinical care of OPGs in order to identify trends in current research and provide an overview to guide future research efforts. Methods This systematic review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The Cochrane Controlled Register of Trials (CENTRAL) and ClinicalTrials.gov were searched. Inclusion and exclusion criteria were applied and final results were reviewed. Results 501 clinical trials were identified with the search strategy. All were screened and eligible studies extracted and reviewed. This yielded 36 ongoing clinical trials, 27 of which were pharmacological agents in phase I-III. The remaining trials were a mixture of biological agents, radiation optimisation, diagnostic imaging, surgical intervention, and a social function analysis. Conclusion OPG is a complex multifaceted disease, and advances in care require ongoing research efforts across a spectrum of different research fields. This review provides an update on the current state of research in OPG and summarises ongoing trials.

The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer

“…Therefore, BRAF inhibitors are reserved for specific indications such as recurrent or refractory cases [ 17 ]. However, targeted therapies are under investigation in low-grade gliomas, such as an upcoming European trial of frontline MEK inhibition or studies of BRAF inhibition in V600E mutated tumours [ 18 ]. Each paediatric cancer specialist group needs to develop updated guidelines where the role, timing and duration of such novel agents is clarified [ 17 , 19 ].…”

Novel “T-Dimension” Therapies for Pediatric Optic Pathway Glioma: A Timely, Targeted, and Tailored Treatment Trend

“…In the past decade, the therapeutic trend for OPGs was toward the innovative molecular targeted therapies, as >50% of the clinical trials were based on the Ras-related pathway and angiogenesis inhibitors [12,17,21,24,26,27,[77][78][79][80][81]. Among all the MEKi, selumetinib and trametinib have proven to have excellent efficacy profiles, especially for recurrent or refractory forms, with a twoyear PFS rate of 70% [82].…”

“…Conventional treatment options historically have included chemoradiotherapy, surgical resection, and radiotherapy [13][14][15][16][17][18][19][20][21]. Nevertheless, recent advances in the field of neuro-oncology have led to a dramatically wider spectrum of cures, mainly through the refinement of epigenetics and techniques in regenerative medicine [12,[22][23][24][25][26][27][28][29][30][31].…”

Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience

“…The choice of the specific molecular inhibitor depends on the underlying biology, making biopsy essential ( 22 , 23 ) to collect biological samples to perform molecular investigations to identify the best tailored treatment ( 49 ).…”